Innovative Solutions That Improve Patients’ Lives

Phibo is a renowned company in the field of digital dentistry and promotes growth and expertise with the aid of innovative solutions that accompany and simplify daily life and improve patients’ lives. In addition to products such as implant systems and CAD/CAM prostheses, Phibo also offers services and digital solutions. Phibo is currently a market Read more about Innovative Solutions That Improve Patients’ Lives[…]

BayPAT’s Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA

BayPAT, a service provider offering services in the area of technology transfer, IP management and commercialisation, today announced that its licensee Recardio is already in the Phase 2 study for regenerative therapy in early recovery post-myocardial infarction in Europe and USA. The regenerative therapy concept of Recardio with its DPP-IV inhibitor dutogliptin is subject to Read more about BayPAT’s Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA[…]

Avoid animal testing – MAT and rFC as persuasive alternatives

Already at the end of the 19th century it became known that injections can cause severe fever in patients. Substances causing this kind of reactions are called pyrogens, which have been analyzed over the following decades very intensely. A first animal (rabbit) test was developed using the fact that rabbits do also develop a fever Read more about Avoid animal testing – MAT and rFC as persuasive alternatives[…]

MDR – an overview

. Introduction The MDR (Medical Device Regulation) is currently a hot topic and is keeping manufacturers of medical products and their suppliers on their toes. There are many different reasons for this. On one hand, the timeline laid out by the EU is extremely ambitious and, on the other, it is not yet clear how Read more about MDR – an overview[…]

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Joint United Nations Programme on HIV/AIDS (UNAIDS) at the organization’s Health Innovation Exchange from May Read more about QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation[…]

QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its novel therascreen® FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) as a companion diagnostic to help guide the use of the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib), developed by Janssen Biotech, Inc. (Janssen). The test will aid in identifying patients Read more about QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer[…]

Novel coating enables hip implants to grow in better and prevents aseptic inflammation

The number of hip prostheses in the EU has risen steadily over the past ten years – most notably in Austria and Germany with 300 implants per 100,000 inhabitants. The frequency of aseptic inflammatory processes between bone and implant, accompanied with loosening of the prosthesis, has increased, resulting in a shortened lifetime of the hip Read more about Novel coating enables hip implants to grow in better and prevents aseptic inflammation[…]

QIAGEN receives approval for EGFR test in lung cancer as companion diagnostic in Japan

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the therascreen® EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s VIZIMPRO® (dacomitinib) for EGFR gene mutation-positive, inoperable or recurrent non-small cell lung cancer. The therascreen® EGFR RGQ PCR Kit is Read more about QIAGEN receives approval for EGFR test in lung cancer as companion diagnostic in Japan[…]

QIAGEN acquires N-of-One, expanding its clinical bioinformatics capabilities in molecular oncology decision support

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One will enable QIAGEN to significantly expand its decision-support solutions while offering a broader range Read more about QIAGEN acquires N-of-One, expanding its clinical bioinformatics capabilities in molecular oncology decision support[…]

QIAGEN to develop QuantiFERON-TB Access as a new test for low-resource, high-burden regions in global fight against TB

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to develop a proprietary new version of a QuantiFERON®-based tuberculosis (TB) test dedicated and tailored to the needs of low-resource regions with a high disease burden of TB. The new testing solution, QuantiFERON®-TB Access (QFT® Access), is designed to pair ultrasensitive digital detection of Read more about QIAGEN to develop QuantiFERON-TB Access as a new test for low-resource, high-burden regions in global fight against TB[…]